Critical Contrast: Tenaya Therapeutics (TNYA) vs. The Competition

Tenaya Therapeutics (NASDAQ:TNYAGet Rating) is one of 255 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Tenaya Therapeutics to related businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, analyst recommendations and dividends.


This table compares Tenaya Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tenaya Therapeutics N/A -50.18% -33.45%
Tenaya Therapeutics Competitors -4,587.78% -67.40% -30.70%

Analyst Ratings

This is a summary of current recommendations and price targets for Tenaya Therapeutics and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenaya Therapeutics 0 0 4 0 3.00
Tenaya Therapeutics Competitors 1669 5771 11413 210 2.53

Tenaya Therapeutics presently has a consensus target price of $36.00, indicating a potential upside of 470.52%. As a group, “Biological products, except diagnostic” companies have a potential upside of 110.56%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

83.4% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tenaya Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tenaya Therapeutics N/A -$72.72 million -0.41
Tenaya Therapeutics Competitors $773.46 million $147.16 million 0.09

Tenaya Therapeutics’ rivals have higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

About Tenaya Therapeutics (Get Rating)

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Want More Great Investing Ideas?

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with's FREE daily email newsletter.